{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-011826","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2026-02-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.589081+00:00","generated_at":"2026-05-16T05:02:28.136796+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Allarity opens Phase 2 trial of stenoparib + temozolomide in relapsed SCLC","bullets":["Enrollment open at 11 VA sites for NCT06681220; trial fully funded by U.S. Department of Veterans Affairs.","Phase 2 evaluates stenoparib (dual PARP/WNT inhibitor) plus temozolomide in recurrent small cell lung cancer.","Study uses a blood-based biomarker to select patients most likely to benefit from the combination.","Stenoparib's favorable safety profile is cited as key rationale for combination with temozolomide.","Stenoparib crosses the blood-brain barrier, offering potential for brain metastases common in advanced SCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-011826","json":"https://secwatch.observer/filing/0001213900-26-011826.json","markdown":"https://secwatch.observer/filing/0001213900-26-011826.md","text":"https://secwatch.observer/filing/0001213900-26-011826.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026011826/0001213900-26-011826-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026011826/ea0275506-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:02:28.136796+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}